Literature DB >> 24528007

HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.

Wen-Ting Chen1, Xiang Gao, Xiao-Dian Han, Hui Zheng, Lin Guo, Ren-Quan Lu.   

Abstract

BACKGROUND AND
PURPOSE: Human epididymis protein 4 (HE4) has been suggested to be a novel biomarker of epithelial ovarian cancer (EOC). The present study aimed to evaluate and compare HE4 with the commonly used marker, carbohydrate antigen 125 (CA125), in prediction and therapy-monitoring of EOC. PATIENTS AND METHODS: Serum HE4 concentrations from 123 ovarian cancer patients and 174 controls were measured by Roche electrochemiluminescent immunoassay (ECLIA). Risk of ovarian malignancy algorithm (ROMA) values were calculated and assessed. In addition, the prospects of HE4 detection for therapy-monitoring were evaluated in EOC patients.
RESULTS: The ROMA score could classify patients into high- and low-risk groups with malignancy. Indeed, lower serum HE4 was significantly associated with successful surgical therapy. Specifically, 38 patients with EOC exhibited a greater decline of HE4 compared with CA125. In contrast, elevation of HE4 better predicted recurrence (of 46, 11 patients developed recurrence, and with it increased HE4 serum concentrations) and a poor prognosis than CA125.
CONCLUSIONS: This study suggests that serum HE4 levels are closely associated with outcome of surgical therapy and disease prognosis in Chinese EOC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528007     DOI: 10.7314/apjcp.2014.15.1.101

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  11 in total

1.  A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression.

Authors:  Nicole E James; Megan Gura; Morgan Woodman; Richard N Freiman; Jennifer R Ribeiro
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.738

Review 2.  The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.

Authors:  L-T Jia; Y-C Zhang; J Li; Y Tian; J-F Li
Journal:  Clin Transl Oncol       Date:  2015-07-29       Impact factor: 3.405

3.  The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.

Authors:  Qiong Zhang; Cong-Rong Wang; Juan-Ping Yu; Qiang Ma; Wei-Wen Xu
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

4.  The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.

Authors:  Yuhui Wang; Zhenming Wang; Yansheng Ding; Fengqiang Sun; Xiaomei Ding
Journal:  Asian Pac J Cancer Prev       Date:  2019-08-01

5.  Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.

Authors:  Yan Rong; Li Li
Journal:  J Ovarian Res       Date:  2021-01-04       Impact factor: 4.234

6.  Overexpression of GOLPH3 protein is associated with worse prognosis in patients with epithelial ovarian cancer.

Authors:  Yingchun Ma; Xiuxia Wang; Yuanhong Wu; Binghui Sun; Hongtao Lv; Fengnian Rong; Xiaoxia Zheng
Journal:  Tumour Biol       Date:  2014-09-10

7.  Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer.

Authors:  Liancheng Zhu; Huiyu Zhuang; Huimin Wang; Mingzi Tan; Carlton L Schwab; Lu Deng; Jian Gao; Yingying Hao; Xiao Li; Song Gao; Juanjuan Liu; Bei Lin
Journal:  Oncotarget       Date:  2016-01-05

8.  Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?

Authors:  Anita Chudecka-Głaz; Aneta Cymbaluk-Płoska; Małgorzata Wężowska; Janusz Menkiszak
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

9.  Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.

Authors:  Xin Wang; Lei Han; Ling Zhou; Li Wang; Lan-Mei Zhang
Journal:  Oncol Rep       Date:  2018-09-13       Impact factor: 3.906

10.  HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect.

Authors:  Duanyang Liu; Dan Kong; Jing Li; Lei Gao; Di Wu; Yu Liu; Weiwei Yang; Lei Zhang; Jiang Zhu; Xiaoming Jin
Journal:  J Ovarian Res       Date:  2018-06-14       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.